Drug Profile
Enoxaparin sodium biosimilar - Harvest Moon Pharmaceuticals
Latest Information Update: 22 Aug 2013
Price :
$50
*
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Anti-ischaemics; Antithrombotics; Ischaemic heart disorder therapies; Low molecular weight heparins
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Myocardial infarction; Thromboembolism; Unstable angina pectoris
Most Recent Events
- 22 Aug 2013 Launched for Myocardial infarction in Latin America (SC)
- 22 Aug 2013 Launched for Thromboembolism (prevention) in Latin America (SC)
- 22 Aug 2013 Launched for Thromboembolism in Latin America (SC)